Telmisartan and Losartan: The Marked Differences Between Their Chemical and Pharmacological Properties May Explain the Difference in Therapeutic Efficacy in Hospitalized Patients with COVID-19

Overview

Journal Pharmacol Res Perspect

Date 2023 Apr 11

PMID 37038324

Authors

Rodolfo Pedro Rothlin

Facundo German Pelorosso

Mariano Duarte

Liliana Nicolosi

Fernandez Criado Ignacio

Maria Victoria Salgado

Hector Vetulli

Affiliations

Soon will be listed here.

Citing Articles

Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients.

Jeong I, Ryu S, Han N, Staatz C, Baek I Clin Pharmacokinet. 2025; 64(2):285-295.

PMID: 39808372 DOI: 10.1007/s40262-024-01471-3.

Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood-Brain Barrier.

Moore G, Ridway H, Kate Gadanec L, Apostolopoulos V, Zulli A, Swiderski J Int J Mol Sci. 2024; 25(11).

PMID: 38891966 PMC: 11171751. DOI: 10.3390/ijms25115779.

Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients.

Mekary W, Fares S, Abdulhai F, Massoud G, Refaat M, Mericskay M Heliyon. 2023; 9(9):e19373.

PMID: 37662725 PMC: 10472216. DOI: 10.1016/j.heliyon.2023.e19373.

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19.

Rothlin R, Pelorosso F, Duarte M, Nicolosi L, Ignacio F, Salgado M Pharmacol Res Perspect. 2023; 11(2):e01083.

PMID: 37038324 PMC: 10086312. DOI: 10.1002/prp2.1083.

References

Bahr I, Tretter P, Kruger J, Stark R, Schimkus J, Unger T . High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension. 2011; 58(4):725-32. DOI: 10.1161/HYPERTENSIONAHA.111.173542. View

Bullock G, Steyaert I, Bilbe G, Carey R, Kips J, De Paepe B . Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol. 2001; 115(2):117-24. DOI: 10.1007/s004180000235. View

Deshotels M, Xia H, Sriramula S, Lazartigues E, Filipeanu C . Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014; 64(6):1368-1375. PMC: 4231883. DOI: 10.1161/HYPERTENSIONAHA.114.03743. View

Rizk J, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E . Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. Drugs. 2021; 82(1):43-54. PMC: 8675115. DOI: 10.1007/s40265-021-01639-2. View

Goncalves J, Santos C, Fresco P, Fernandez-Llimos F . Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Rev Port Cardiol. 2023; 42(4):373-383. PMC: 9999244. DOI: 10.1016/j.repc.2022.02.014. View

Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A . Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021; 4(3):e213594. PMC: 8013817. DOI: 10.1001/jamanetworkopen.2021.3594. View

Liu D, Wu P, Gu W, Yang C, Yang X, Deng X . Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs. Cell Discov. 2022; 8(1):91. PMC: 9462647. DOI: 10.1038/s41421-022-00454-7. View

Zhang G, Wu Y, Xu R, Du X . Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis. J Med Virol. 2020; 93(4):2287-2300. PMC: 7753790. DOI: 10.1002/jmv.26695. View

Rothlin R, Pelorosso F, Duarte M, Nicolosi L, Ignacio F, Salgado M . Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacol Res Perspect. 2023; 11(2):e01083. PMC: 10086312. DOI: 10.1002/prp2.1083. View

10.

Offringa A, Montijn R, Singh S, Paul M, Pinto Y, Pinto-Sietsma S . The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Eur Heart J Cardiovasc Pharmacother. 2020; 6(5):317-325. PMC: 7314063. DOI: 10.1093/ehjcvp/pvaa053. View

11.

Petek B, Villa-Lopez M, Loera-Valencia R, Gerenu G, Winblad B, Kramberger M . Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. J Intern Med. 2018; 284(6):620-642. DOI: 10.1111/joim.12838. View

12.

Zhang P, Zhu L, Cai J, Lei F, Qin J, Xie J . Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; 126(12):1671-1681. PMC: 7265882. DOI: 10.1161/CIRCRESAHA.120.317134. View

13.

Kow C, Ramachandram D, Hasan S . Effects of Angiotensin II Receptor Blockers on the Risk of Mortality in Patients with COVID-19: An Updated Systematic Review and Meta-analysis of Randomized Trials. Am J Hypertens. 2022; 35(8):763-764. PMC: 9384267. DOI: 10.1093/ajh/hpac070. View

14.

Burnier M . Telmisartan: a different angiotensin II receptor blocker protecting a different population?. J Int Med Res. 2010; 37(6):1662-79. DOI: 10.1177/147323000903700602. View

15.

Pascual G, Fong A, Ogawa S, Gamliel A, Li A, Perissi V . A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005; 437(7059):759-63. PMC: 1464798. DOI: 10.1038/nature03988. View

16.

Piplani S, Singh P, Winkler D, Petrovsky N . In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021; 11(1):13063. PMC: 8225877. DOI: 10.1038/s41598-021-92388-5. View

17.

Lam K, Chow K, Vo J, Hou W, Li H, Richman P . Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. J Infect Dis. 2020; 222(8):1256-1264. PMC: 7454718. DOI: 10.1093/infdis/jiaa447. View

18.

Theodorakopoulou M, Alexandrou M, Boutou A, Ferro C, Ortiz A, Sarafidis P . Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. Clin Kidney J. 2022; 15(3):397-406. PMC: 8754739. DOI: 10.1093/ckj/sfab272. View

19.

Das A, Dhanure S, Savalia A, Nayak S, Tripathy S . Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions. Indian J Pharm Sci. 2015; 77(2):190-5. PMC: 4442468. DOI: 10.4103/0250-474x.156583. View

20.

Duarte M, Pelorosso F, Nicolosi L, Salgado M, Vetulli H, Aquieri A . Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021; 37:100962. PMC: 8225700. DOI: 10.1016/j.eclinm.2021.100962. View